histiocytic sarcoma
Recently Published Documents


TOTAL DOCUMENTS

565
(FIVE YEARS 159)

H-INDEX

30
(FIVE YEARS 4)

Author(s):  
Jourdan B. McPhetridge ◽  
Valery F. Scharf ◽  
Penny J. Regier ◽  
Darby Toth ◽  
Max Lorange ◽  
...  

Abstract OBJECTIVE To provide updated information on the distribution of histopathologic types of primary pulmonary neoplasia in dogs and evaluate the effect of postoperative adjuvant chemotherapy in dogs with pulmonary carcinoma. ANIMALS 340 dogs. PROCEDURES Medical records of dogs that underwent lung lobectomy for removal of a primary pulmonary mass were reviewed, and histopathologic type of lesions was determined. The canine lung carcinoma stage classification system was used to determine clinical stage for dogs with pulmonary carcinoma. RESULTS Pulmonary carcinoma was the most frequently encountered tumor type (296/340 [87.1%]), followed by sarcoma (26 [7.6%]), adenoma (11 [3.2%]), and pulmonary neuroendocrine tumor (5 [1.5%]); there was also 1 plasmacytoma and 1 carcinosarcoma. Twenty (5.9%) sarcomas were classified as primary pulmonary histiocytic sarcoma. There was a significant difference in median survival time between dogs with pulmonary carcinomas (399 days), dogs with histiocytic sarcomas (300 days), and dogs with neuroendocrine tumors (498 days). When dogs with pulmonary carcinomas were grouped on the basis of clinical stage, there were no significant differences in median survival time between dogs that did and did not receive adjuvant chemotherapy. CLINICAL RELEVANCE Results indicated that pulmonary carcinoma is the most common cause of primary pulmonary neoplasia in dogs; however, nonepithelial tumors can occur. Survival times were significantly different between dogs with pulmonary carcinoma, histiocytic sarcoma, and neuroendocrine tumor, emphasizing the importance of recognizing the relative incidence of these various histologic diagnoses. The therapeutic effect of adjuvant chemotherapy in dogs with pulmonary carcinoma remains unclear and warrants further investigation.


Author(s):  
Miyuki Hirabayashi ◽  
James K. Chambers ◽  
Takuya E. Kishimoto ◽  
Nguyen V. Son ◽  
Yuichi Ishikawa ◽  
...  

Author(s):  
Caroline A. Murray ◽  
Jennifer L. Willcox ◽  
Carlos H. De Mello Souza ◽  
Brian Husbands ◽  
Matthew R. Cook ◽  
...  

Author(s):  
Alessandro Feola ◽  
Paola Ciamarra ◽  
Mariavictoria De Simone ◽  
Anna Carfora ◽  
Gelsomina Mansueto ◽  
...  

Background: Haematological malignancies, such as lymphoma and leukaemia, can have a variety of clinical manifestations. The most frequent cause of death from haematological malignancies is multiple organ failure due to neoplastic organ infiltration and/or septic shock. Histiocytic sarcoma (HS) is a rare malignant nodal or extranodal tumour with histiocytic immunophenotype that originates from a lymphohematopoietic precursor. The patients with HS usually have a poor prognosis due to its aggressive clinical behaviour. Rare cases of undiagnosed sudden HS death have been described in the literature. Methods: A forensic autopsy of a 46-year-old white male who died at home suddenly and unexpectedly without warning conditions or known diseases. Gross analysis, histology and toxicology were also performed. Results: The diagnosis of HS of the ileum with secondary nodal and cardiac metastatization was made. Conclusions: A prompt diagnosis of HS in life is paramount because it can make a difference in prognostic outcomes.


2021 ◽  
Vol 11 ◽  
Author(s):  
Zijian Liu ◽  
Yin Xiao ◽  
Xinxiu Liu ◽  
Qiuhui Li ◽  
Tao Liu ◽  
...  

BackgroundHistiocytic sarcoma (HS) is a rare hematopoietic malignancy with an aggressive clinical presentation associated with a poor overall survival. To date, surgical resection, radiation therapy, and chemotherapy were often utilized for HS, but curative effects are rather disappointing.Case PresentationA 19-year-old female was referred to our hospital with a pathologic diagnosis of HS in December 2017. The patient had a severe airway obstruction resulting from a large mass (6.0 cm × 4.4 cm) arising from the left parapharyngeal space. She did not respond to cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOEP) chemotherapy, then she was switched to radiotherapy and crizotinib according to next-generation sequencing (NGS) results (mutations in MET and MAP2K1). The patient got a partial response after radiotherapy and crizotinib, then she switched to imatinib combined with thalidomide treatment. The patient got a long-term complete response from the treatment and is alive 44 months after initial diagnosis without disease progression. Further KEGG pathway enrichment analysis of NGS results from patient’s tissue revealed that phosphatidylinositol 3′ kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) pathways were activated in this HS patient. We further performed experiments in vitro in a canine histiocytic sarcoma cell line DH82, in order to explore the possible mechanism of imatinib plus thalidomide in HS. Results of cell counting kit-8 (CCK8) assays showed that the proliferation activity of DH82 was significantly inhibited by imatinib but not thalidomide. Combined thalidomide and imatinib treatment did not improve the inhibitory effects of imatinib to DH82. Results of Western blot confirmed the inhibitory effects of imatinib on DH82 by targeting activation of MAPK and PI3K/AKT pathways.ConclusionRadiotherapy combined with targeted therapy guided by NGS may be promising, and further perspective clinical trial is warranted for the localized HS.


2021 ◽  
pp. 168-173
Author(s):  
Clevio Desouza ◽  
Girish Nathani ◽  
Amol Patil ◽  
Amit Kale

2021 ◽  
Vol 38 (5) ◽  
pp. 249-253
Author(s):  
Hee-Soo Cho ◽  
Jong-Tae Cheong ◽  
Hyun-Jung Park ◽  
Jae-Hoon Kim ◽  
Ji-Youl Jung ◽  
...  
Keyword(s):  

Author(s):  
Carmit Chalfon ◽  
Giovanni Romito ◽  
Silvia Sabattini ◽  
Antonella Rigillo ◽  
Manuela Quinci ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document